Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Hickory Point Bank & Trust

Hickory Point Bank & Trust lowered its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 34.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,595 shares of the biopharmaceutical company’s stock after selling 2,417 shares during the period. Hickory Point Bank & Trust’s holdings in Bristol-Myers Squibb were worth $280,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. LaFleur & Godfrey LLC lifted its position in Bristol-Myers Squibb by 3.5% during the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company’s stock valued at $2,463,000 after buying an additional 1,487 shares in the last quarter. Brighton Jones LLC raised its stake in shares of Bristol-Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the period. Silver Oak Securities Incorporated lifted its holdings in shares of Bristol-Myers Squibb by 76.4% during the 4th quarter. Silver Oak Securities Incorporated now owns 6,997 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 3,030 shares in the last quarter. Leo Wealth LLC boosted its position in Bristol-Myers Squibb by 51.5% during the 4th quarter. Leo Wealth LLC now owns 14,965 shares of the biopharmaceutical company’s stock worth $846,000 after purchasing an additional 5,085 shares during the period. Finally, Strategic Financial Concepts LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at $4,377,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $48.42 on Friday. The stock has a market capitalization of $98.54 billion, a PE ratio of -10.95, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38. The business’s fifty day moving average price is $49.34 and its 200 day moving average price is $55.04. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the business posted ($4.40) EPS. Equities research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BMY. Jefferies Financial Group lowered their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. Piper Sandler assumed coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price target for the company. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Wall Street Zen downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $58.00.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 4,250 shares of the company’s stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.